Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever
- PMID: 1915397
- DOI: 10.1007/BF01967272
Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever
Abstract
Cancer patients were randomized to receive an every 4 hour or every 8 hour schedule of cefoperazone plus aztreonam during 617 febrile episodes. The overall response rate for the 478 evaluable episodes was 76% and there was no difference in response rate between the two schedules. The response rate was 79% for cases of pneumonia and 63% for cases of bacteremia. Only 50% of the microbiologically documented infections caused by gram-positive organisms responded whereas 95% of gram-negative infections, including all of those caused by Pseudomonas aeruginosa, responded. Response rates were lower among patients whose neutrophil counts decreased during therapy than among those whose neutrophil counts increased (64% vs. 85%, p = 0.008). Side-effects that were possibly or probably related to antibiotic therapy were observed during 11% of the episodes. The most common side-effects were diarrhea and rashes including one case of Stevens-Johnson syndrome. Three patients developed a coagulopathy during therapy. Cefoperazone plus aztreonam proved to be an effective combination for treatment of gram-negative infections and fever of unknown origin in cancer patients and an every 8-hour schedule of administration was as effective as an every 4-hour schedule. Approximately half of the patients with gram-positive infections required additional antibiotics for successful therapy.
Similar articles
-
Cefoperazone plus piperacillin versus mezlocillin plus tobramycin as empiric therapy for febrile episodes in neutropenic patients.Am J Med. 1988 Jul 25;85(1A):36-43. doi: 10.1016/0002-9343(88)90173-8. Am J Med. 1988. PMID: 3041817 Clinical Trial.
-
An open trial of cefoperazone plus sulbactam for the treatment of fever in cancer patients.J Antimicrob Chemother. 1993 Jul;32(1):141-52. doi: 10.1093/jac/32.1.141. J Antimicrob Chemother. 1993. PMID: 8226405 Clinical Trial.
-
A comparison of aztreonam plus vancomycin and imipenem plus vancomycin as initial therapy for febrile neutropenic cancer patients.Cancer. 1996 Apr 1;77(7):1386-94. doi: 10.1002/(SICI)1097-0142(19960401)77:7<1386::AID-CNCR25>3.0.CO;2-X. Cancer. 1996. PMID: 8608520 Clinical Trial.
-
Aztreonam in the prevention and treatment of infection in neutropenic cancer patients.Am J Med. 1990 Mar 23;88(3C):24S-29S; discussion 38S-42S. doi: 10.1016/0002-9343(90)90084-q. Am J Med. 1990. PMID: 2180294 Review.
-
Preservation of colonization resistance parameters during empiric therapy with aztreonam in the febrile neutropenic patient.Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S747-61. doi: 10.1093/clinids/7.supplement_4.s747. Rev Infect Dis. 1985. PMID: 3909333 Review.
Cited by
-
Outcomes of treatment pathways in outpatient treatment of low risk febrile neutropenic cancer patients.Support Care Cancer. 2004 Sep;12(9):657-62. doi: 10.1007/s00520-004-0613-6. Support Care Cancer. 2004. PMID: 15185134 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical